Tucatinib and Trastuzumab in Patients With Previously Treated HER2-Positive Metastatic BTC: The SGNTUC-019 Study

This phase 2 basket study investigated the combination of tucatinib and trastuzumab as second-line treatment for patients with HER2-positive biliary tract cancer.

The optimal second-line therapy for patients with advanced biliary tract cancer (BTC) remains unclear. Current second-line treatment options, such as FOLFOX and S-1, have modest clinical benefit with limited overall response rates (ORRs) and suboptimal median overall survival (OS).1-3 Targeted therapies, such as those targeting HER2, are of increasing interest as second-line treatment options for patients with actionable mutations.4 HER2 overexpression or amplification is observed in up to 20% of patients with BTC, and some case studies and single-arm prospective studies have suggested therapeutic potential with HER2-targeted therapy.1,4 Tucatinib is an oral HER-selective tyrosine kinase inhibitor currently approved for HER2-positive metastatic breast cancer and metastatic colorectal cancer following progression on previous therapy.5 Yoshiaki Nakamura, MD, PhD, presented findings from the SGNTUC-019 (NCT04579380) study, which investigated tucatinib with trastuzumab in patients with previously treated metastatic HER2-positive BTC, at the ASCO 2023 annual meeting.6

Yoshiaki Nakamura, MD, PhD, presented findings from the SGNTUC-019 (NCT04579380) study, which investigated tucatinib with trastuzumab in patients with previously treated metastatic HER2-positive BTC.

SGNTUC-019 is an open-label, phase 2 basket study that evaluated the antitumor activity and safety of tucatinib and trastuzumab in patients with HER2-altered solid tumors.6 Enrolled patients had unresectable locally advanced or metastatic cancer previously treated with ≥1 prior lines of systemic therapy with no history of HER2-directed treatment.6 Patients with BTC who had HER2 overexpression or amplification were assigned to cohort 3.6 Treatment consisted of a 21-day cycle with tucatinib 300 mg orally twice a day and trastuzumab intravenously every 3 weeks.6 The primary end point was confirmed ORR, and key secondary end points included safety, disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and OS.6

A total of 30 patients with BTC were enrolled, all of whom received ≥1 doses of tucatinib or trastuzumab.6 The mean study follow-up was 10.8 months. Of the 30 patients, 8 had extrahepatic cholangiocarcinoma (CCA), 7 had intrahepatic CCA, and 15 had gallbladder cancer.6 Patients had an average of 2 prior lines of therapy in any setting.6 The confirmed ORR was 46.7%, 1 patient had a complete response, and 13 had a partial response.6 The median DOR was 6 months, the median time to first response was 2.1 months, the DCR was 76.7%, and 70% of patients had a reduction in tumor size.6 The median PFS was 5.5 months and median OS was 15.5 months.6 All patients had ≥1 treatment-emergent adverse event (TEAE), 18 patients had a grade ≥3 TEAE, and 13 patients had a serious TEAE.6 Most grade ≥3 and serious TEAEs were not related to tucatinib (7 patients with tucatinib-related grade ≥3 TEAEs, 3 patients with tucatinib-related serious AEs).6 The most common grade ≥3 TEAEs were nausea, decreased appetite, and cholangitis, each in 3 patients.6 In addition, 3 patients had a TEAE leading to discontinuation of any study treatment (3 tucatinib, 1 trastuzumab), and there were no TEAEs leading to death.6

Overall, the combination of tucatinib and trastuzumab demonstrated antitumor activity in patients with previously treated HER2-positive BTC, with an ORR of 46.7%.6 Tucatinib plus trastuzumab was well tolerated with low rates of discontinuation and no treatment-related deaths.6 Results from this study indicate that HER2 is an actionable target in BTC and should be further explored in larger studies.


  1. Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943-962.
  2. Suzuki E, Ikeda M, Okusaka T, et al. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol. 2013;71(5):1141-1146.
  3. Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690-701.
  4. Harding JJ, Piha-Paul SA, Shah RH, et al. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun. 2023;14(1):630.
  5. TUKYSA [package insert]. Bothell, WA: Seagen Inc; 2023.
  6. Nakamura Y. Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): a phase 2 basket study. Presented at: ASCO 2023 Annual Meeting, June 2-6, 2023; Chicago, IL.

Related Items

First-Line Treatment of Advanced Biliary Tract Cancers (BTCs)
Ask the Expert
Use of first-line (1L) IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin (gem-cis) chemotherapy in patients with locally advanced or metastatic biliary tract cancers
KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review: Cholangiocarcinoma
In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer.
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
2023 Year in Review: Cholangiocarcinoma
This post-hoc analysis of the ABC-01, -02, and -03 clinical trials provides reference survival data for patients with advanced extrahepatic cholangiocarcinoma treated with first-line gemcitabine/cisplatin chemotherapy.
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
2023 Year in Review: Cholangiocarcinoma
Investigators pooled data from 3 trials to evaluate tinengotinib in patients with advanced, refractory/relapsed cholangiocarcinoma who previously received an FGFR inhibitor.
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
2023 Year in Review: Cholangiocarcinoma
Researchers evaluated KLF5 expression and its inhibition in cholangiocarcinoma using clustered regularly interspaced short palindromic repeats technology.
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
2023 Year in Review: Cholangiocarcinoma
In this ongoing phase 2 study, the efficacy of SHR-1316 plus IBI310 is being evaluated in patients with advanced intrahepatic cholangiocarcinoma after inadequate response to first-line therapy.
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
2023 Year in Review: Cholangiocarcinoma
Dr Mahmood presented results from the largest multi-institutional review of efficacy outcomes following targeted agents in patients with cholangiocarcinoma.
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
2023 Year in Review: Cholangiocarcinoma
In the phase 2 component of the phase 2/3 BEER-BTC study, bevacizumab plus erlotinib improved outcomes in patients with advanced biliary tract cancers.
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
2023 Year in Review: Cholangiocarcinoma
Researchers investigated the efficacy and safety of neoadjuvant durvalumab plus gemcitabine/cisplatin (GemCis) versus GemCis alone in patients with biliary tract cancer.
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
2023 Year in Review: Cholangiocarcinoma
In the ongoing phase 2 ADJUBIL study, the clinical activity of immunotherapies durvalumab and tremelimumab with or without capecitabine is being assessed in patients with resectable biliary tract cancer in the adjuvant setting.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: